Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease - Wanner, Christoph; Lachin, John M.; Inzucchi, Silvio E.; Fitchett, David; Mattheus, Michaela; George, Jyothis; Woerle, Hans J.; Broedl, Uli C.; von Eynatten, Maximilian; Zinman, Bernard (Circulation (New York, N.Y.), 2018)
Keywords: Aged; Albuminuria - mortality; Albuminuria - physiopathology; Benzhydryl Compounds - adverse effects; Benzhydryl Compounds - therapeutic use; Cardiovascular Diseases - diagnosis; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - mortality; Cardiovascular Diseases - physiopathology; Cause of Death; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - mortality; Diabetes Mellitus, Type 2 - physiopathology; Female; Glomerular Filtration Rate - drug effects; Glucosides - adverse effects; Glucosides - therapeutic use; Hospitalization; Humans; Kidney - drug effects; Kidney - physiopathology; Male; Middle Aged; Prevalence; Renal Insufficiency, Chronic - diagnosis; Renal Insufficiency, Chronic - drug therapy; Renal Insufficiency, Chronic - mortality; Renal Insufficiency, Chronic - physiopathology; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors - adverse effects; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Time Factors; Treatment Outcome; mortality; sodium-glucose transporter 2; diabetes mellitus, type 2; hospitalization; treatment outcome; kidney diseases